1、M UpdateBiopharma|North America Clinical Trial Pipeline TrackerMorgan Stanley&Co.LLCTerence C Flynn,Ph.D.Equity Analyst Terence.F +1 212 761-2230 Sean Laaman,Ph.D.Equity Analyst Sean.L +1 212 761-4947 Michael E UlzEquity Analyst Mike.U +1 212 761-4650 Judah C.Frommer,CFAEquity Analyst Judah.F +1 212

2、 761-1270 Maxwell SkorEquity Analyst Maxwell.S +1 212 761-4804 Chris Yu,J.D.,Ph.D.Equity Analyst Chris.L.Y +1 212 761-2535 Alexander Yevdokimov,Ph.D.Research Associate Alexander.Y +1 212 761-2167 Hailey HorowitzResearch Associate Hailey.H +1 212 761-5264 Mia D BongiornoResearch Associate Mia.B +1 21

3、2 761-2857 Katherine SunResearch Associate Katherine.S +1 212 761-5968 Michael H Riad,Ph.D.Research Associate Michael.R +1 212 761-1309 Rohit BhasinResearch Associate Rohit.B +1 212 761-0534 Selena ZhangResearch Associate Selena.Z +1 212 761-1017 Morgan K GrygaResearch Associate Morgan.G +1 212 761-

4、0824 Major PharmaceuticalsNorth AmericaIndustry ViewIn-LineBiotechnologyNorth AmericaIndustry ViewAttractiveWe highlight key changes to the clinical trials of companies under coverage occurring from 7/2-7/9.See inside for a full list of all changes.M New Trials(Exhibit 1)Biohaven:The company has ini

5、tiated a Ph1 trial(NCT07054684)of BHV-1400 in IgA Nephropathy.Exelixis/Merck:The company has initiated a Ph1/2 trial(NCT07049926)of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy(MK-3475-03C/KEYMAKER-U03).Suspended(Exhibit

6、2)BioNTech:The Ph2 trial(NCT06534983)to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma(MIUC)has been suspended.Withdrawn(Exhibit 3)N/ATerminated(Exhibit 4)N/ARecruiting(Exhibit 5)BeOne M